NOV 27, 2018 2:27 PM PST

A Genetic Switch During Inflammation

WRITTEN BY: Nicholas Breehl

Wouldn’t it be great to better understand the mechanisms at play behind the scenes with regards to neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and brain cancer? Studies have been conducted to analyze these diseases; however, the activity of neuronal cells such as microglia during acute neuro-inflammatory processes such as those caused by infection, remain to be described.

A recent study performed at the NorLux Neuro-Oncology Laboratory at Luxembourg Institute of Health’s Department of Oncology reveals distinct gene expression profiles for microglial cells by way of single-cell-transcriptomics. Differences in genetic profiles are seen at steady state conditions, acute inflammatory conditions and neurodegenerative diseases. The details surrounding the observations with this study might accelerate future studies on therapeutic approaches to reestablish the central nervous system (CNS) cell function.

Microglia are specialized parenchymal‐resident phagocytes of the CNS that actively support, defend and modulate the neural environment. In other words, the microglia are surveying their surroundings to modulate the neural environment and protect against infection, toxin, or other contamination to promote brain health — Microglia coordinate immune responses between the periphery and the CNS as they perceive and propagate inflammatory signals initiated outside the CNS. Dysfunctional microglial reactions are thought to worsen CNS diseases.

The collaboration at the LIH between Dr. Alessandro Michelucci and Dr. Carole Sousa has facilitated the findings published in the November 2018 publishing of EMBO. Using single‐cell transcriptomics and multicolor flow cytometry this study presents comprehensive profiles of microglia in LPS‐injected mice, providing insight into microglia heterogeneity, and establishing a resource for the identification of specific phenotypes in CNS disorders. LPS stands for lipopolysaccharide. In this study, it is used to induce inflammation in the mouse model for observation. LPS works for this reason because it is what immunologists commonly refer to as a “PAMP” or pathogen-associated-molecular-pattern. Other common PAMPs include porins, peptidoglycan, lipoteichoic acids, mannose-rich glycans, flagellin, bacterial and viral genomes, mycolic acid, and lipoarabinomannan.

The researchers determine that microglia homeostatic signatures are mainly lost upon systemic inflammation, inflammation-induced microglia segregate into two distinct states and inflammation-induced microglia signatures are different from neurodegenerative disease-associated profiles. Disruption of CNS homeostasis, neuronal deterioration and inflammation are common pathophysiological features of several neurodegenerative diseases.

The researchers observed a marked global downregulation of the typical microglial homeostatic signature and simultaneously an up-regulation of genes classically activated by inflammation. 'When investigating further and comparing to published data, we could show that when being under acute systemic inflammation, microglia presented a highly activated state that is distinct from neurodegenerative disease-associated profiles,' states Dr. Sousa, who performed most of the experimental work.

Interestingly, the team observed heterogeneity among the activated cells, to which they hypothesize there may be a subset of reactive microglia less sensitive to the LPS stimulus. The findings will, hopefully, contribute to the establishment of new resources to unveil specific responses to brain disorders. Dr. Michelucci shares, “this should boost the development of novel therapeutic strategies against CNS diseases with an immunological component.”

For more information surrounding the basics of inflammation, watch this video.

Sources: EMBO, Science Daily, YouTube

About the Author
You May Also Like
JUL 29, 2021
Drug Discovery & Development
What is Ivermectin and Can it Treat COVID?
JUL 29, 2021
What is Ivermectin and Can it Treat COVID?
Lab tests in 2020 found that the widely available drug ivermectin had a weak effect on the SARS-CoV-2 virus and that unf ...
AUG 05, 2021
Immunology
Nosedive: Poor Nasal Antiviral Responses Linked to Severe COVID
AUG 05, 2021
Nosedive: Poor Nasal Antiviral Responses Linked to Severe COVID
Talking, singing, coughing—all of these can spread COVID-19 from an infected person via respiratory aerosols. Thes ...
AUG 19, 2021
Immunology
Immune Enzyme Kills Viruses but Makes Tumors Stronger
AUG 19, 2021
Immune Enzyme Kills Viruses but Makes Tumors Stronger
Robert Louis Stevenson’s 1886 novel Strange Case of Dr. Jekyll and Mr. Hyde describes a man who is a kind, respect ...
AUG 31, 2021
Immunology
Convalescent Plasma Therapy for COVID-19 Doesn't Work
AUG 31, 2021
Convalescent Plasma Therapy for COVID-19 Doesn't Work
After encountering an infectious agent, the immune system begins churning out antibodies—Y-shaped warriors that ne ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
SEP 13, 2021
Microbiology
Flu Season Looms Large as World May Have an 'Immunity Debt'
SEP 13, 2021
Flu Season Looms Large as World May Have an 'Immunity Debt'
Scientists are beginning to speculate about the possibility that the flu season this year will be particularly bad becau ...
Loading Comments...